Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SKX +25.9%, TEAM +12%, CAI +6.6%, ERIC +6.3%, PYPL +5.1%, IMPV+5.1%, CGA +4.8%, CVTI +4.2%, MXIM +3.8%, SYF +3%, HA +2.4%, CLW+2.1%, TCFC +0.7%, HON +0.6%, KSU +0.5%
Other news:
- AVGR +23.7% (initiates INSIGHT study to evaluate Pantheris Lumivascular Atherectomy System for treating in-stent restenosis in lower extremity arteries)
- QURE +13.5% (continued momentum)
- ONVO +9.3% (presents 'preclinical data showing extended survival and sustained functionality of its 3D bioprinted human liver tissue)
- RDHL +8.3% (confirms the FDA granted MESUPRON Orphan Drug designation for the adjuvant treatment of pancreatic cancer)
- IMDZ +8.2% (confirms the EMA granted Orphan Drug Designation for G100)
- GIGA +6.7% (thinly traded - nt agreement with Spanawave and Liberty Test )
- REN +3.9% (upgraded to Buy from Neutral at Goldman )
- SYF +3% (ahead of earnings)
- OMER +3% (presents report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy nd graft-versus-host disease, which both resolved following OMS721 treatment)
- VBLT +2.5% (announces that the EMA has designated ofranergene obadenovec)
- FL +1.8% (SKX sympathy)
- MU +1.7% (attributed to Appaloosa's David Tepper comments at the Robin Hood conference)
- BIDU +1.3% (Baidu.com signed strategic cooperation agreements with China automotive companies BAIC Group and Xiamen King Long United Automotive Industry)
Analyst comments:
- REN +3.9% (upgraded to Buy from Neutral at Goldman)
- SSYS +2.4% (upgraded to Positive from Neutral at Susquehanna
- STLD +2% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
- LULU +2% (upgraded to Buy from Neutral at Citigroup)
- SGEN +1.2% (upgraded to Overweight from Equal Weight at Barclays)
- HOG +1% (upgraded to Buy from Hold at Argus)
- LEN +0.8% (upgraded to Buy from Neutral at Citigroup)